The Relevance of Hyperuricemia and Metabolic Syndrome and the Effect of Blood Lead Level on Uric Acid Concentration in Steelmaking Workers

Deul Lee, Won-Jun Choi, Jae-Seok Oh, Min-Kee Yi, Sung-Woo Han, Jong-Wan Yun and Sang-Hwan Han*

Abstract

Objectives: Uric acid concentration is known to increase the prevalence of metabolic syndrome by affecting its components, resulting in increased risk of cerebrovascular and cardiovascular diseases, and long-term lead exposure is known to affect this serum uric acid level. In this study, we aimed to examine the association between the causes of hyperuricemia and metabolic syndrome, and to determine whether an increased blood lead level affects hyperuricemia.

Method: Anthropometric measurements, surveys, and blood tests were conducted between May and June 2012 in 759 men working in the steelmaking process at a domestic steel company. Workers were divided into 2 groups according to the presence or absence of hyperuricemia, and an analysis was performed to examine its association with metabolic syndrome. In addition, the workers were divided into 3 groups according to the blood lead level to analyze the association between blood lead and hyperuricemia.

Results: The geometric mean (standard deviation) of the blood lead levels in the hyperuricemia group was significantly higher than that of the healthy group (3.8 [1.8] vs. 3.3 [1.8] μg/dL). The adjusted odds ratio for metabolic syndrome of the hyperuricemia group increased significantly to 1.787 (1.125–2.839) compared with the healthy group. In addition, the adjusted odds ratios for the occurrence of hyperuricemia in the tertile 2 (2.61–4.50 μg/dL) and tertile 3 groups (>4.50 μg/dL) according to blood lead level significantly increased to 1.763 (1.116–2.784) and 1.982 (1.254–3.132), respectively, compared with the tertile 1 group (< 2.61 μg/dL).

Conclusion: Hyperuricemia is believed to function as an independent risk factor for metabolic syndrome, while lead seems to increase the serum uric acid level even at a considerably low blood level. Therefore, attention should be given to patients with hyperuricemia and metabolic syndrome who are prone to lead exposure, and a prospective study should be conducted to identify their causal relationship.

Keywords: Lead, Uric acid, Metabolic syndrome

Introduction

According to the 2011 Statistics Korea data on domestic causes of death, cerebrovascular and heart diseases ranked second and third, respectively, among the 3 leading causes of death in Korea as yet [1]. Moreover, according to a report, 278 of 731 occupational disease-related deaths in 2011 were due to cerebrovascular and cardiovascular diseases [2]. As such, the prevention of occupational cerebrovascular and cardiovascular diseases is gaining importance along with continuous efforts of many businesses and health institutions to develop practical preventive measures through the management of metabolic syndromes that involve various cerebrovascular and cardiovascular risk factors.

Various studies have identified metabolic syndromes as a major predictor of cerebrovascular and cardiovascular diseases [3], and study results indicated that the occurrence and progression of cerebrovascular and cardiovascular diseases can be prevented through strict management of metabolic syndrome [4].
Recently, continuous reports have emerged on the association between metabolic syndrome, cerebrovascular and cardiovascular diseases, and serum uric acid level, which is well known to be a causal factor for gout. Gradually accumulated evidence support that serum uric acid level has a significant correlation with each component of a metabolic syndrome, as it causes hypertension and insulin resistance and is involved in changes in blood triglycerides and cholesterol levels while being associated with obesity and complications of metabolic syndromes [5,6].

Existing studies conducted with the general population or workers reported their analysis results that hyperuricemia significantly correlated with blood lead concentrations [7]. Meanwhile, the results of other studies verified relatively high serum uric acid levels and high incidence rates of gout in people with long-term lead exposure [8,9]; as such, an integrated approach for the management of long-term lead exposure and hyperuricemia, as well as metabolic syndrome, is necessary from the perspective of occupational environment medicine.

Until the present, only a few domestic studies have analyzed the relationship between hyperuricemia and metabolic syndrome; in particular, it is difficult to find domestic and international case studies analyzing the relationship between occupational lead exposure, hyperuricemia, and metabolic syndrome. Therefore, this study aimed to examine the relationship between blood lead level and serum uric acid concentration, and the association between hyperuricemia and the occurrence of metabolic syndrome in male workers involved in steelmaking [10], which requires the most number of lead handling processes among metal industries.

Materials and methods

Subject

Health screenings were conducted for a domestic steelmaker between May 15 and June 5, 2012, in which 2,133 of total 2,157 target workers were screened. Among the target workers, most were male workers, accounting for 2,097 subjects (97.2%), 765 (36.5%) of whom were working in the steelmaking process. Among them, 759 male workers participated in the survey. Excluding the 6 male steelmaking workers who did not participate in the anthropometry or blood testing or who provided inadequate responses to the survey, a total of 759 workers were finally selected as research subjects.

Anthropometric measurements and surveys

Height and weight were measured using an automatic body measurement device, and a tape measure was used to measure the waist circumference on the midpoint between the bottom part of the ribs and the upper part of the pelvic bones horizontal to the ground. Blood pressure was measured using an automatic blood pressure measuring system after more than 5 minutes of steady state; when the systolic and diastolic pressures were 140 and 90 mm Hg or higher, respectively, the lower value was selected after a repeated measurement taken after more than 10 minutes of rest. Body mass index (BMI) was calculated by dividing weight (kg) by the square of height (m).

Through a self-reported survey, medical history of hypertension, diabetes, and dyslipidemia, and the use of medication therapy, smoking and drinking habits, and exercise, were examined. Survey data on smoking and drinking habits (considering the different types of alcohol) were presented in pack-years and days/week, respectively. Exercise was defined as a minimum of 20 minutes of workout per day until feeling out of breath and was expressed in frequency (days/week).

Blood and urine tests

After at least 8 hours of fasting, venous blood samples were collected from the subjects and fasting glucose, total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, aspartate aminotransferase (AST), alanine aminotransferase (ALT), γ-glutamyl transpeptidase (γ-GTP), creatinine, blood lead, and serum uric acid concentrations were measured. The blood lead concentration analysis was performed using atomic absorption spectrophotometry (AAnalyst 600, PerkinElmer, Finland), and serum uric acid concentration was measured using Uricase EMST method (Hitachi 747 automatic analyzer, Hitachi, Tokyo, Japan). For low-density lipoprotein (LDL) cholesterol, the value calculated using the Friedewald formula, LDL (mg/dL) = TC (mg/dL) – HDL (mg/dL) – TG (mg/dL)/5, was used when the triglyceride level was lower than 400 mg/dL and the direct measurement method through the homogenous method was used if the triglyceride level exceeded 400 mg/dL.

Definition of metabolic syndrome

By applying the criteria of the American Heart Association/National Heart Lung and Blood Institute published in 2005 [11], metabolic syndrome was defined when 3 or more of the following 5 risk factors were applicable: (1) waist circumference of 90 cm or greater, (2) blood triglyceride concentrations of 150 mg/dL or higher or being under medication therapy, (3) blood HDL level lower than 40 mg/dL or being under medication therapy, (4) systolic pressure of 130 mm Hg or higher or diastolic pressure of 85 mm Hg or higher or being under medication therapy, and (5) fasting glucose level of 100 mg/dL or higher or being under medication therapy.

Statistical analysis

Statistical analysis was performed using SPSS (version 18.0). Hyperuricemia was defined as a serum uric acid
concentration of higher than 7.0 mg/dL [12], and a t test was performed to determine whether a hyperuricemia-dependent difference existed in the anthropometric measurements, blood test results, and living habits. As blood lead concentration showed a distribution skewed to the left, geometric means and standard deviations were calculated after performing natural log transformation. To analyze the relationship between hyperuricemia and metabolic syndrome, we performed a logistic regression analysis. For variables other than hyperuricemia, a multivariate logistic regression analysis was performed by including them in the model as confounding variables after confirming multicollinearity. In addition, the relationship between blood lead concentration and hyperuricemia was analyzed. Blood lead concentration was set as an explanatory variable by classifying it in tertiles, and a multivariate logistic regression analysis was performed by including them in the model as confounding variables after confirming multicollinearity among other variables, excluding the components of metabolic syndrome.

Results

Hyperuricemia-dependent clinical characteristics of the subjects

The healthy (without hyperuricemia) group had 577 subjects, and the hyperuricemia group had 182 subjects. The mean (standard deviation) for serum uric acid concentration was 5.5 (0.9) mg/dL in the healthy group and 7.8 (0.7) mg/dL in the hyperuricemia group (Table 1). Compared with the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the hyperuricemia group, fasting glucose and triglycerides, AST, ALT, γ-GTP, and serum creatinine levels were significantly higher compared to those in the healthy group. Weekly drinking frequency was significantly higher but weekly exercise frequency was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the hyperuricemia group, fasting glucose and triglycerides, AST, ALT, γ-GTP, and serum creatinine levels were significantly higher compared to those in the healthy group. Weekly drinking frequency was significantly higher but weekly exercise frequency was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group. In the healthy group, the mean age was significantly lower and the mean waist circumference and BMI were significantly higher in the hyperuricemia group.

Relationship between hyperuricemia and the occurrence of metabolic syndrome

Hyperuricemia was found to be significantly associated with the occurrence of metabolic syndrome through the univariate (model 1; Table 2) and multivariate logistic regression analyses, the latter being adjusted for age and blood lead concentration (model 2); additionally adjusted for smoking, drinking, and exercise habits (model 3); and for LDL-cholesterol, γ-GTP, and serum creatinine levels (model 4). In addition, age and γ-GTP level were found to be significantly associated with metabolic syndrome.

Association between blood lead concentration and the occurrence of hyperuricemia

In the univariate logistic regression analysis (model 1), the odds ratio for hyperuricemia increased as the blood lead concentration increased in relation to 1 quartile (Table 3). Blood lead concentration was found to have a significant association with hyperuricemia in the multivariate logistic regression analysis models respectively adjusted for age, BMI, and γ-GTP level (model 2); additionally adjusted for smoking, drinking, and exercise habits (model 3); and adjusted for serum creatinine (model 4). In addition, a significant association was observed between hyperuricemia, and BMI, γ-GTP level, smoking habit, and serum creatinine level, among which serum creatinine level particularly showed a high odds ratio of 16.877, indicating a very high degree of association with hyperuricemia.

Table 1: Hyperuricemia-dependent clinical characteristics of the subjects

| Variables                        | Normal (N = 577) | Hyperuricemia† (N = 182) | p-value |
|----------------------------------|------------------|---------------------------|---------|
|                                  | Mean (SD)        | Mean (SD)                 |         |
| Age (years)                      | 42.3 (10.9)      | 38.1 (10.5)               | 0.000   |
| Waist circumference (cm)         | 83.5 (7.2)       | 85.5 (7.5)                | 0.001   |
| Body mass index (kg/m²)          | 24.1 (2.6)       | 24.9 (2.9)                | 0.001   |
| Systolic blood pressure (mmHg)   | 118.3 (12.1)     | 119.8 (11.5)              | 0.135   |
| Diastolic blood pressure (mmHg)  | 76.2 (9.7)       | 77.4 (9.8)                | 0.142   |
| Fasting blood glucose (mg/dL)    | 98.5 (21.4)      | 94.0 (11.5)               | 0.000   |
| Total cholesterol (mg/dL)        | 194.0 (34.6)     | 199.7 (34.9)              | 0.054   |
| LDL-cholesterol (mg/dL)          | 110.0 (30.7)     | 110.6 (34.8)              | 0.829   |
| HDL-cholesterol (mg/dL)          | 54.0 (11.9)      | 51.1 (10.9)               | 0.004   |
| Triglyceride (mg/dL)             | 157.0 (116.0)    | 209.0 (161.4)             | 0.000   |
| AST (IU/L)                       | 24.5 (13.3)      | 28.7 (14.7)               | 0.001   |
| ALT (IU/L)                       | 27.4 (25.8)      | 35.2 (27.3)               | 0.001   |
| γ-GTP (IU/L)                     | 44.0 (46.7)      | 59.2 (60.8)               | 0.002   |
| Serum creatinine (mg/dL)         | 0.9 (0.1)        | 1.0 (0.1)                 | 0.000   |
| Smoking (pack-year)              | 10.7 (11.9)      | 11.2 (11.6)               | 0.622   |
| Drinking (days/week)             | 1.7 (1.9)        | 1.9 (1.3)                 | 0.037   |
| Exercise (days/week)             | 1.8 (1.7)        | 1.5 (1.7)                 | 0.029   |
| Blood lead (µg/dL)              | 3.3 (1.8)        | 3.8 (1.8)                 | 0.003   |

*: p < 0.05 by t-test.
†: Serum uric acid level ≥7 mg/dL.
‡: Geometric mean (Geometric standard deviation).
This study examined the association between hyperuricemia and metabolic syndrome, and the association between blood lead and serum uric acid concentrations. Hyperuricemia showed a significant association with metabolic syndrome even in the results adjusted for confounding variables, whereas lead was shown to be associated with hyperuricemia even at low blood concentrations.

According to existing studies [13,14], an increase in serum uric acid concentration is thought to partially contribute to an increase in blood pressure via the activation of the renin-angiotensin-aldosterone system by inducing renal vascular inflammation, preglomerular arteriolopathy, tubulointerstitial inflammation and fibrosis. Serum uric acid concentration also seems to interfere with blood vessel expansion by decreasing the response of blood vessels.

### Table 2 Multiple logistic regression analysis demonstrating relationship between hyperuricemia and metabolic syndrome* in four models

| Variables               | Model 1          | Model 2          | Model 3          | Model 4          |
|-------------------------|------------------|------------------|------------------|------------------|
| Hyperuricemia (≥7 mg/dL)|                  |                  |                  |                  |
| No                      | 1.000            | 1.000            | 1.000            | 1.000            |
| Yes                     | 1.533 (1.014 ~ 2.317) | 2.016 (1.296 ~ 3.135) | 1.939 (1.242 ~ 3.026) | 1.787 (1.125 ~ 2.839) |
| Age (years)             | 1.057 (1.037 ~ 1.077) | 1.055 (1.032 ~ 1.077) | 1.049 (1.026 ~ 1.073) |                  |
| log transformed blood lead (µg/dL) | 0.855 (0.414 ~ 1.768) | 0.822 (0.394 ~ 1.715) | 0.789 (0.370 ~ 1.681) |                  |
| Smoking (pack-year)     | 1.007 (0.991 ~ 1.024) | 1.005 (0.988 ~ 1.022) |                  |                  |
| Drinking (days/week)    | 1.035 (0.996 ~ 1.183) | 0.948 (0.820 ~ 1.097) |                  |                  |
| Exercise (days/week)    | 0.941 (0.837 ~ 1.057) | 0.969 (0.861 ~ 1.091) |                  |                  |
| LDL-cholesterol (mg/dL) | 1.002 (0.996 ~ 1.008) |                  |                  |                  |
| γ-GTP (IU/L)            | 1.008 (1.005 ~ 1.012) |                  |                  |                  |
| Serum creatinine (mg/dL)| 0.433 (0.077 ~ 2.442) |                  |                  |                  |

* Defined as the presence of at least three of the following components: waist circumference ≥90 cm, triglycerides ≥150 mg/dL or on drug treatment, HDL-cholesterol < 40 mg/dL or on drug treatment, SBP ≥130 or DBP ≥85 mmHg or on drug treatment, and fasting glucose ≥100 mg/dL or on drug treatment.

Model 1: not adjusted.
Model 2: adjusted by age, log transformed blood lead.
Model 3: adjusted for model 2 plus smoking, drinking, exercise.
Model 4: adjusted for model 3 plus LDL-cholesterol, γ-GTP, serum creatinine.

### Table 3 Multiple logistic regression analysis demonstrating association between blood lead level and hyperuricemia* in four models

| Variables                | Model 1          | Model 2          | Model 3          | Model 4          |
|--------------------------|------------------|------------------|------------------|------------------|
| Tertile group (blood lead, µg/dL) |                  |                  |                  |                  |
| I (< 2.61)               | 1.000            | 1.000            | 1.000            | 1.000            |
| II (2.61 ~ 4.50)         | 1.676 (1.091 ~ 2.576) | 1.971 (1.258 ~ 3.087) | 1.902 (1.211 ~ 2.989) | 1.763 (1.116 ~ 2.784) |
| III (>4.50)              | 1.890 (1.236 ~ 2.889) | 2.286 (1.460 ~ 3.579) | 2.182 (1.389 ~ 3.430) | 1.982 (1.254 ~ 3.132) |
| Age (years)              | 0.951 (0.934 ~ 0.967) | 0.943 (0.924 ~ 0.962) | 0.945 (0.925 ~ 0.965) |                  |
| Body mass index (kg/m²)  | 1.098 (1.031 ~ 1.168) | 1.099 (1.033 ~ 1.170) | 1.096 (1.030 ~ 1.168) |                  |
| γ-GTP (IU/L)             | 1.006 (1.003 ~ 1.010) | 1.005 (1.002 ~ 1.009) | 1.005 (1.002 ~ 1.009) |                  |
| Smoking (pack-year)      | 1.017 (0.999 ~ 1.035) | 1.020 (1.002 ~ 1.039) |                  |                  |
| Drinking (days/week)     | 1.076 (1.044 ~ 1.126) | 1.085 (1.051 ~ 1.238) |                  |                  |
| Exercise (days/week)     | 0.950 (0.853 ~ 1.058) | 0.938 (0.841 ~ 1.046) |                  |                  |
| Serum creatinine (mg/dL) |                  |                  |                  | 16.877 (3.388 ~ 84.073) |

* Serum uric acid level ≥7 mg/dL.

Model 1: not adjusted.
Model 2: adjusted by age, body mass index, γ-GTP.
Model 3: adjusted for model 2 plus smoking, drinking, exercise.
Model 4: adjusted for model 3 plus serum creatinine.
to acetylcholine and to increase blood pressure by causing endothelial dysfunction through interference in the excretion process of nitric oxide (NO) from vascular endothelial cells by expressing toxicity directly on the blood vessels [15,16]. In this regard, a study reported that when the activity of xanthine oxidase, which is involved in the uric acid generation process, was inhibited by administering allopurinol to patients, blood flow was improved along with vasodilation [17].

Whether serum uric acid level independently influences the increase in blood glucose level is controversial. While there are reports on increased insulin resistance due to certain serum uric acid levels increasing blood flow and causing vasodilation to interfere with the action of nitric oxide, which facilitates glucose absorption [18], other results suggest that hyperuricemia is caused by hyperinsulinemia due to insulin resistance acting on the renal tubules to facilitate the reabsorption of uric acid [19,20]. These results suggest an interaction between uric acid and insulin levels. However, the mean fasting glucose level in the hyperuricemia group was significantly lower than that in the healthy group in this study, contradicting the results of existing studies. Upon considering the results of recent related studies, a decreased fasting glucose level in patients with hyperuricemia is possibly due to the increase in uric acid excretion caused by the glomerular hyperfiltration when hyperglycemia is maintained [21,22]. However, additional research is necessary in the future to validate this hypothesis.

The effects of serum uric acid level on dyslipidemia have not yet been clearly identified; however, according to recent studies, the increase in uric acid concentration seems to reduce the function of lipid peroxidase and lipoprotein lipase, which are involved in lipolysis, while the process of decreased nitric oxide excretion from blood vessels is believed to affect the progression of dyslipidemia [23,24]. In this study, the total cholesterol and LDL-cholesterol levels in the hyperuricemia group were not statistically significant, but the mean levels were still higher compared to those in the healthy group. Meanwhile, triglyceride levels were significantly higher in the hyperuricemia group, with significantly lower HDL-cholesterol levels, than in the healthy group. In particular, the levels of the triglycerides related to metabolic syndrome showed the greatest difference in mean values when compared with the other parameters, which seems to be due to the decreased function of the tricarboxylic acid cycle with the increased oxidative stress in the mitochondria of liver cells as the uric acid synthesis increased due to purine metabolism, resulting in slower triglyceride metabolism and an increase in lipogenesis [25].

Regarding the association between obesity and serum uric acid concentration, it is known that obese individuals mostly consume meat, with high intake of purine, which results in an increase in uric acid concentration [26], and hyperuricemia is caused by the facilitation of uric acid reabsorption in the renal tubules due to high insulin resistance. These results point to obesity as the cause of hyperuricemia [27,28]. However, based on the various correlations identified so far, such as the close association between insulin resistance and nitric oxide synthesis dysfunction in vascular endothelial cells and the claim that uric acid interferes with the nitric oxide excretion process [18], the increase in the risk for fatty liver in proportion to the purine metabolism-induced uric acid synthesis triggered by the deterioration in mitochondria function in liver cells [25], and the contribution of the reduced mitochondria functioning to the fat accumulation in muscles and liver in a study with a non-obese elderly population [29], hyperuricemia itself seems to partially contribute to obesity. This finding warrants additional research in the future.

In this study, the hyperuricemia group showed a significantly higher mean blood lead concentration than that in the healthy group. The subjects’ geometric mean (standard deviation) blood lead concentration was approximately 3.4 (1.8) μg/dL, which was significantly lower than 25.0 μg/dL [30], the blood lead concentration designated by the Centers for Disease Control and Prevention (CDC) as affecting the physiological health of adults, and even below the recommended upper limit level of 5.0 μg/dL for children in 2012 [31]. However, in our univariate and multivariate regression analyses, the risk of hyperuricemia was shown to increase even at low blood lead concentrations between 2.61 and 4.50 μg/dL.

Uric acid is synthesized through the metabolism of purine, and humans are known to have a relatively high level of serum uric acid concentration compared with other mammals, as humans do not possess the enzyme for metabolizing uric acid [32]. Therefore, to maintain an appropriate level of serum uric acid, males need to excrete a daily volume of 600–700 mg of uric acid through the glomeruli, and proximal and distal tubules of the kidney; ascending loop; and collecting duct. If kidney functioning is reduced, the probability of hyperuricemia becomes relatively high [33]. Furthermore, in this study, serum creatinine level and hyperuricemia showed a positive association, which is consistent with the existing study results that renal functioning affects serum uric acid levels.

In fact, according to recent studies, an increase in blood lead concentration caused a reduction in estimated glomerular filtration rate (eGFR) even at a blood lead concentration lower than 10.0 μg/dL [34]. In addition to the glomeruli, blood lead causes the atrophy and hyperplasia of the tubular epithelial cells and increases the risk for hyperuricemia by reducing secretory functions to cause interstitial fibrosis and inflammation [7,35,36]. In
addition, when blood lead concentration is higher than 1.2 μg/dL, the risk for gout reportedly increases with the reduction in uric acid excretion ability of the kidney [37].

An independent association with hyperuricemia was observed for smoking and γ-GTP level; however, it is too early to assume that both are direct risk factors for hyperuricemia, as existing studies report inconsistent results, suggesting the need to conduct a prospective study [38-40].

The steelmaking company investigated in this study was an independent steelmaker largely divided into steelmaking and rolling processes. The steelmaking process exposes workers to lead fumes during the dissolving process, during which metal containing impurities is melted [41]. In fact, according to a study that measured ambient lead concentration using individual samples during the steelmaking process, most of the samples showed lead concentrations exceeding 50% of the domestic threshold (0.05 mg/m³), indicating that the steelmaking process require attention regarding occupational lead exposure, along with the iron making process, in which metal is extracted by dissolving ore [41-43]. In addition, the workers involved in ironmaking processes were exposed to mineral dust, noise, hyperthermia, sulfur dioxide (SO₂), carbon monoxide (CO), and hydrogen sulfide (H₂S), but none of the causative factors of hyperuricemia identified by previous studies was found.

This study has its significance in providing results that controlled task properties and sex by limiting the subjects to male workers from a steelmaking company known to have the most number of lead handling processes among other metal industries, in comparison with existing studies that did not match task properties while targeting the general public or workers as subjects. It is also significant in that its simultaneous analyses revealed that hyperuricemia is significantly associated with metabolic syndrome and that low levels of blood lead can affect hyperuricemia.

This study has the following limitations: First, it is a cross-sectional study, and a causal relationship between blood lead level, serum uric acid level, and metabolic syndrome could not be established while attempting to explain the intervariable relationships using various studies in the existing literature. Second, recall bias might have existed, as the smoking, drinking, and exercise habits, and drug therapy were examined through surveys; this bias was minimized through the comparison between existing survey data for identical subjects. Third, no survey was conducted on diet related to serum uric acid concentration; it was partially controlled as the workers took the same meal twice a day at the company canteen while working 3 shifts, but a more accurate investigation needs to be conducted. Lastly, as it is an analysis for a particular group, our study was limited in generalizing the results to all population groups. In a group without occupational exposure, identical physiological mechanisms due to blood lead levels were reported [44]. However, a study with a general population group is needed in the future.

At present, with the prevention and management of workplace workers' cerebrovascular and cardiovascular diseases becoming increasingly important, attention should be given to serum uric acid concentration, which has been regarded as a causal factor only for gout. In particular, from the perspective of occupational environment medicine, hyperuricemia should be managed in individuals who are likely to be exposed to lead over a longer period of time for occupational and environmental reasons. The results of this study suggest that a risk for hyperuricemia exists even at low blood lead concentrations. Thus, it is necessary to conduct a large-scale prospective study to identify any causal relationship.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
DL and WJC designed the research and performed the statistical analysis. JSO, MKY and SHW collected the data. JWY and SHH revised the manuscript. All of the authors read and approved the final manuscript.

Received: 31 May 2013 Accepted: 13 September 2013
Published: 25 October 2013

References
1. Statistics Korea: Causes of Death Statistics in 2011. Korea; 2011.
2. Ministry of Employment and Labor: Analysis of the industrial disaster status in Korea 2011. Korea; 2011.
3. Delker JM, Gitman C, Rhodes T, Nippeis G, Stehouwer CD, Bouter LM, Heine RJ: Metabolic syndrome and 10-year cardiovascular disease risk in the hoorn study. Circulation 2005, 112:666–673.
4. Chan WP, Sverdlov AL, Horowitz JD: Management of the metabolic syndrome in cardiovascular disease. Curr Treat Options Cardiovasc Med 2008, 10:27–38.
5. Feig DI, Kang DH, Johnson RJ: Uric acid and cardiovascular risk. N Engl J Med 2008, 359:1811–1821.
6. Baker JE, Krishnan E, Chen L, Schumacher HR: Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med 2005, 118:816–826.
7. Weaver VM, Jaar BG, Schwartz BS, Todd AC, Ahn KD, Lee SS, Wen J, Parsons PJ, Lee BK: Associations among lead dose biomarkers, uric acid, and renal function in Korean lead workers. Environ Health Perspect 2004, 113:35–42.
8. Shadick NA, Kim R, Weiss S, Liang MH, Sparrow D, Hu H: Effect of low level lead exposure on hyperuricemia and gout among middle aged and elderly men: the normative aging study. J Rheumatol 2000, 27:1708–1712.
9. Lin JL, Tan DT, Ho HH, Yu CC: Environmental lead exposure and urate excretion in the general population. Am J Med 2002, 113:563–569.
10. Occupational safety and health team of Gyeonggi seobu area office: KOSHA. Korea: Survey on the status of using lead and its compounds in Korea; 2008.
11. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. 2005. http://www.idf.org.
12. Lee K: Relationship between uric acid and hepatic steatosis among Koreans. Diabet Med 2009, 35:470–474.
13. Mazzali M, Kanelis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ: Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:991–997.
14. Sundstrom J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS: Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 2005, 45:28–33.
15. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, Johnson RJ: Hypothesis: uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 2004, 66:281–287.
16. Hwang S, Lee KE, Lee BH, Gwak JH, Yoo JH, Choi YH: Relationship between serum uric acid level and hypertension: a retrospective cohort study. Korean J Fam Med 2010, 31:622–628. Korean.
17. Feig DI, Slezanksy B, Johnson RJ: Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924–932.
18. Khosla UM, Zharkov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia induces endothelial dysfunction. Kidney Int 2005, 67:1739–1742.
19. Yoo TW, Sung KC, Shin HS, Kim BJ, Kim BS, Kang JH, Lee MH, Park JR, Kim H, Rheo EJ, Lee WY, Kim SW, Ryu SH, Keurn DG: Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005, 69:298–303.
20. Nakanishi N, Okamoto M, Yoshida H, Matsu Y, Suzuki K, Tatara K: Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol 2003, 18:523–530.
21. Li Q, Yang Z, Lu B, Wen J, Ye Z, Chen L, He M, Tao X, Zhang W, Huang Y, Zhang Q, Su H, R: Serum uric acid level and its association with metabolic syndrome and carotid atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol 2011, 10:1–7.
22. Shabana S, Sreeekala M, Satyanayana U: Uric acid in relation to type 2 diabetes mellitus associated with hypertension. J Clin Diag Res 2012, 6:1110–1113.
23. Heimbach EJ, Bowden RG, Griggs JO, Beaujean AA, Doyle EI, Doyle RD: The effects of lowering uric acid levels using allopurinol on components of metabolic syndrome. Cardiol Res 2012, 3:80–86.
24. Nakagawa T, Hu H, Zharkov S, Tuttle RK, Short RA, Shluchkova O, Ouyang X, Feig DI, Block ER, Herrera-Acosta I, Patel JM, Johnson RJ: A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol 2006, 290:F625–631.
25. Lanaspa MA, Sanchez-Lozada LG, Choi YJ, Ciccheri C, Kanbay M, Roncalli-Jimenez CA, Ishimoto T, Li N, Marek G, Duranay M, Schreiner G, Rodriguez-Iiturbe B, Nakagawa T, Kang DH, Sautin YY, Johnson RJ: Uric acid induces hepatic steatosis by generation of mitochondrial oxidative stress: potential role in fructose-dependent and independent fatty liver. J Biol Chem 2012, 287:40732–40744.
26. Song JS: Clinical manifestations and diagnosis of gout. J Korean Med Assoc 2010, 53:695–704. Korean.
27. Gil-Campesi M, Aguilera CM, Canete R, Gil A: Uric acid is associated with features of insulin resistance syndrome in obese children at prepubertal stage. Nutr Hosp 2009, 24:607–613.
28. Baldwin W, McRae S, Marek G, Wymer D, Panou V, Baylis C, Johnson RJ, Sautin YY: Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. Diabetes 2011, 60:1258–1269.
29. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI: Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003, 300:1140–1142.
30. Centers for Disease Control and Prevention (CDC): Adult blood lead epidemiology and surveillance–United States, 2005–2007. Morb Mortal Wkly Rep 2009, 58:365–369.
31. Centers for Disease Control and Prevention (CDC): Low lead level exposure harms children: a renewed call for primary prevention. USA, 2012.
32. Alvarez-Lario B, Macarron-Vicente J: Uric acid and evolution. Rheumatology (Oxford) 2010, 49:2010–2015.
33. de Oliveira EP, Burini RC: High plasma uric acid concentration: causes and consequences. Diabetol Metab Syndr 2012, 4:1–7.
34. Kim Y, Lee BK: Associations of blood lead, cadmium, and mercury with estimated glomerular filtration rate in the Korean general population: analysis of 2008–2010 Korean national health and nutrition examination survey data. Environ Res 2012, 118:124–129.
35. Gotch FC: Nephrotoxicity of cadmium & lead. Indian J Med Res 2008, 128:335–352.
36. Missoum F, Slimani M, Aoues A: Toxic effect of lead on kidney function in rat wistar. Afr J Biochem Res 2014, 8:211–27.